These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19628084)

  • 1. Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy.
    Abolmaali K; Balakrishnan A; Stearns AT; Rounds J; Rhoads DB; Ashley SW; Tavakkolizadeh A
    Surgery; 2009 Aug; 146(2):269-73. PubMed ID: 19628084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
    Jacobs BA; Deenen MJ; Pluim D; van Hasselt JG; Krähenbühl MD; van Geel RM; de Vries N; Rosing H; Meulendijks D; Burylo AM; Cats A; Beijnen JH; Huitema AD; Schellens JH
    Br J Clin Pharmacol; 2016 Sep; 82(3):706-16. PubMed ID: 27161955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
    Mauritz R; van Groeningen CJ; Smid K; Jansen G; Pinedo HM; Peters GJ
    Int J Cancer; 2007 Jun; 120(12):2609-12. PubMed ID: 17330233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
    Milano G; Chamorey AL
    Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.
    Taniguchi M; Yano M; Tsujinaka T; Ogawa A; Morita S; Kaneko K; Akiyama Y; Miki H; Monden M
    In Vivo; 2003; 17(3):219-23. PubMed ID: 12929570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
    Jensen SA; Vainer B; Sørensen JB
    Int J Cancer; 2007 Feb; 120(3):694-701. PubMed ID: 17096352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
    Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
    Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma.
    Akhter K; Enamur Rashid M
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):503-508. PubMed ID: 30803213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer.
    Ota D; Kusama M; Kaise H; Nakayama S; Misaka T; Tsuchida A; Aoki T
    Breast Cancer; 2004; 11(4):356-66. PubMed ID: 15604991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers].
    Barrat MA; Renée N; Mormont MC; Milano G; Levi F
    Pathol Biol (Paris); 2003 Jun; 51(4):191-3. PubMed ID: 12852985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in penile cancer].
    Zhao F; Tang J; Gou HF; Li LH; Dong H; Chen Y; Cheng K; Ding J; Chen X; Men HT; Liu JY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):756-9. PubMed ID: 24325106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
    Baba H; Teramoto K; Kawamura T; Mori A; Imamura M; Arii S
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):469-76. PubMed ID: 13680162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
    Bai W; Wu Y; Zhang P; Xi Y
    Int J Clin Exp Pathol; 2015; 8(10):12333-45. PubMed ID: 26722420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
    Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
    Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
    Milano G; Etienne MC
    Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
    Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
    Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Lee A; Ezzeldin H; Fourie J; Diasio R
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.